127 related articles for article (PubMed ID: 31928627)
1. Trk receptor tyrosine kinases in metastasis and cancer therapy.
Regua AT; Doheny D; Arrigo A; Lo HW
Discov Med; 2019 Oct; 28(154):195-203. PubMed ID: 31928627
[TBL] [Abstract][Full Text] [Related]
2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
4. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
5. Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW; Hawkins DS
Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
[No Abstract] [Full Text] [Related]
6. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
8. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.
Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202
[TBL] [Abstract][Full Text] [Related]
9. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
10. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
11. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.
Wong D; Yip S; Sorensen PH
Pathol Oncol Res; 2020 Jul; 26(3):1385-1399. PubMed ID: 31256325
[TBL] [Abstract][Full Text] [Related]
12. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.
Chen Y; Chi P
J Hematol Oncol; 2018 Jun; 11(1):78. PubMed ID: 29880008
[TBL] [Abstract][Full Text] [Related]
13. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
14. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Kummar S; Lassen UN
Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
17. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
19. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophin signaling via Trks and p75.
Friedman WJ; Greene LA
Exp Cell Res; 1999 Nov; 253(1):131-42. PubMed ID: 10579918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
